Under-reporting of harm in clinical trials

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Safety

Background:

• Assessing the benefit-risk ratio of anticancer drugs requires robust safety evaluations.
• Existing clinical trial methodologies may lead to under-reporting of drug-induced harm.
• Patient-reported outcomes are often not adequately captured in current trial designs.

Purpose of the Study:

• To highlight deficiencies in current anticancer drug safety evaluations within clinical trials.
• To propose improvements in clinical trial conduct, oversight, and reporting.
• To emphasize the need for real-world data on drug tolerability.

Main Methods:

• Review of existing evidence on harm under-reporting in clinical trials.
• Analysis of factors contributing to under-reporting (e.g., clinician assessment, reporting bias, limited follow-up).
• Discussion of limitations of trial populations for generalizable practice.

Main Results:

• Clinician assessments of harm may not align with patient experiences.
• Investigator reporting and sponsor influence can compromise harm detection and reporting.
• Short follow-up periods fail to capture long-term toxicities.
• Trial participant selection may limit the applicability of findings to diverse patient populations.

Conclusions:

• Clinical trial designs need enhancement with patient-reported outcome measures for side-effects.
• Robust pharmacovigilance programs and large-scale observational studies are crucial.
• Improved methods are necessary to accurately understand anticancer drug tolerability in real-world settings.